PROBLEM TO BE SOLVED: To provide antibodies, particularly monoclonal antibodies capable of being used in the treatment and diagnosis of Alzheimer's disease (AD), central nervous system cell degeneration, learning and memory impairment, abnormal transport of amyloid β, and other neurological inflammatory symptoms associated with a receptor for advanced-glycation-end-products (RAGE).SOLUTION: The invention provides isolated monoclonal antibodies with an antigen binding domain which can bind to the epitope of a human RAGE molecule, or a RAGE molecular binding fragment thereof, wherein the antigen binding domain is a heavy chain variable (VH) region and a light chain variable (VL) region.SELECTED DRAWING: None
ANTIBODIES TO RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS (RAGE) AND USES THEREOF